Review top news and interview highlights from the week ending November 26, 2021.
The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.
In 26 patients with LBCL followed for at least 28 days, the objective response rate (ORR) was 58% with complete responses (CRs) in 38% of patients.
The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s ex-vivo and in-vivo gene therapy platforms.
Pfizer and Sangamo voluntarily paused the trial after participants experienced FVIII activity levels of over 150%.
The professor from National Taiwan University Hospital discussed the benefits of delivering gene therapy directly to the putamen in AADC deficiency.